New DNA sequencing strategy could be vital during disease outbreak

EU-funded scientists have developed a strategy to rapidly identify the genetic properties of virulent strains of bacteria. Such techniques will be essential in responding effectively to an epidemic of a new strain of a disease or a bioterrorist attack.

Thanks to traditional DNA sequencing technologies, researchers have succeeded in sequencing the genomes of over 450 species of bacteria, including representative strains of all major human pathogens. However, this process is extremely slow, and in the case of an outbreak or terrorist attack, scientists need to determine the pathogen's genome as soon as possible so that they can determine which virulence genes or drug resistance genes the bacteria has.

Recently, techniques have been developed which enable scientists to sequence an entire bacterial genome in a matter of hours. However, the finishing steps required to obtain the complete sequence are still very time consuming. In this latest study, scientists in France and Sweden investigated whether enough information to mount a response to an outbreak could be obtained by using a rapidly sequenced, incomplete genome and comparing it to existing genomes for the same species. Their results are published online by the journal Genome Research.

They tested their theory on a strain of Francisella tularensis, a highly infectious bacterium that causes a disease called tularaemia. People catch the disease from the bite of an infected tick, while handling infected animal carcasses or by eating or drinking contaminated food or water. Symptoms include fever, chills, headaches, diarrhoea, muscle and joint pain and progressive weakness. If left untreated, it can be fatal. The scientists chose it for their study because there are strong concerns that it could be genetically manipulated for use as a biological weapon.

"In the context of an outbreak, a quick approach may help to identify immediately the genetic determinants responsible for modified virulence or transmission," explained Dr Bernard La Scola of the University of the Mediterranean in France.

Dr La Scola and his colleagues used rapid sequencing technology to obtain the genome of a strain of F. tularensis taken from a patient suffering from tularaemia. They were able to identify a number of genes linked to virulence as well as a mutation associated with quinolone resistance. The researchers were also able to distinguish their strain from 80 other strains of F. tularensis.

"We demonstrated that this strategy was efficient to detect gene polymorphisms such as a gene modification responsible for antibiotic resistance, and loss of genetic material," commented Dr La Scola.

According to the team, with enough researchers working on the project, the time from DNA extraction to complete genome analysis can be cut to just six weeks. Dr Scola believes that future advances in the software used to analyse and compare genome sequences could cut this time still further.

EU support for the research came from the EU-funded EuroPathoGenomics Network of Excellence, which is funded under the 'Life sciences, genomics and biotechnology for health' thematic area of the Sixth Framework Programme (FP6).

For more information, please visit:
http://www.genome.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...